Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...

Last September, the FIBRONEER-IPF trial also showed an improvement in lung function with the drug in patients with idiopathic pulmonary fibrosis (IPF), another ILD subtype that tends to be less ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim ...

Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...

Significant research news last week included a setback for Pliant Therapeutics, when it paused a Phase IIb trial of its bexotegrast in idiopathic pulmonary fibrosis (IPP). Also, US biotech AnaptysBio ...

United Therapeutics (UTHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in ...

Shares in the UK's IP Group slid today after it revealed that an arthritis drug in development at one of its portfolio ...

Pliant Therapeutics (NASDAQ:PLRX) stock, currently trading at $3.23, maintained a Buy rating and a $32.00 price target from Stifel analysts following recent developments in the company's clinical ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...